# US 2025/0367205 A1 · Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367205 A1
- Document ID: US20250367205A1
- Status: Published application
- Kind: A1
- Application number: 19/302,476
- Filed: 2025-08-18
- Published: 2025-12-04
- Earliest claimed: 2019-09-18
- Assignees: Prelude Therapeutics Incorporated
- Applicants: Prelude Therapeutics, Incorporated
- Inventors: Ganfeng Cao; Qun Li; Huaping Zhang; Hongwu Yu
- Web page: https://patentgrep.com/patent/US20250367205A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07H 19/14: Pyrrolo-pyrimidine radicals
- A61P 35/00: Antineoplastic agents
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure is directed to pharmaceutically acceptable salts of the compound of Formula I (I). Pharmaceutical compositions comprising pharmaceutically acceptable salts of the compound of Formula I, as well as methods of their use and preparation, are also described.

## Claims

### Claim 1

A pharmaceutical composition comprising a crystalline salt of compound with Formula I:
and a pharmaceutically acceptable excipient, wherein the crystalline salt is a hydrochloride salt with Formula IA:

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt form is Formula IA-Form I, characterized by an X-ray powder diffraction pattern comprising a peaks at 21.2, 23.8, 27.0, and 32.5 degrees±0.2 degrees 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt form is Formula IA-Form II, characterized by an X-ray powder diffraction pattern comprising peaks at 14.8, 17.5, 18.4, 24.0, 25.5, 28.0, and 28.7 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt form is Formula IA-Form IIa, characterized by an X-ray powder diffraction pattern comprising peaks at 12.5, 14.0, 14.9, 18.4, and 26.1 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt form is Formula IA-Form III, characterized by an X-ray powder diffraction pattern comprising peaks at 8.1, 12.5, 13.7, 14.5, 16.2, 18.8, 23.3, and 24.5 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt is Formula IA-Form IV, characterized by an X-ray powder diffraction pattern comprising peaks at 4.0, 22.7, and 27.8 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt form is a phosphate salt of the compound of Formula I.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the crystalline salt form is Formula IB-Form I, characterized by an X-ray powder diffraction pattern comprising peaks at 18.2, 19.6, 24.9 25.7, and 27.0 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the crystalline salt form is Formula IB-Form II, characterized by an X-ray powder diffraction pattern comprising peaks at 19.3, 22.3, 23.6, 24.6, and 27.4 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the crystalline salt form is a tartrate salt of the compound of Formula I having Formula IC, characterized by an X-ray powder diffraction pattern comprising peaks at 18.4, 19.4, 19.9, 21.5, and 26.3 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

### Claim 11 (depends on 1)

A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a pharmaceutical composition of any of the claim 1 in combination with one or more therapeutic agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition can be administered in combination with an immune checkpoint inhibitor.

### Claim 13 (depends on 11)

The method of claim 11 wherein, the pharmaceutical composition can be administered in combination with one or more chemotherapeutic agents.

### Claim 14 (depends on 1)

A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a pharmaceutical composition of claim 1.

### Claim 15

A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject a crystalline HCl salt of Formula IA:

### Claim 16 (depends on 15)

The method of claim 15, wherein the disease or disorder associated with aberrant PRMT5 activity is breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, cervical cancer, leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), epidermoid cancer, hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD), CDKN2A deleted cancers; 9P deleted cancers; MTAP deleted cancers; spliceosome mutant cancers, glioblastoma, NSCLC, head and neck cancer, bladder cancer, hepatocellular carcinoma, adenoid cystic carcinoma (ACC), primary central nervous system lymphoma, fallopian tube cancer, or non-Hodgkin lymphoma.

### Claim 17

A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a pharmaceutical composition comprising a crystalline salt of compound of Formula IA:
and a pharmaceutically acceptable excipient in combination with one or more therapeutic agent.

### Claim 18 (depends on 17)

The method of claim 17, wherein the therapeutic agent is one or more chemotherapeutic agents.

### Claim 19 (depends on 17)

The method of claim 17, wherein the therapeutic agent is an immune checkpoint inhibitor.

### Claim 20 (depends on 17)

The method of claim 17, wherein the therapeutic agent is one or more chemotherapeutic agents.
